Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Lineage Cell Therapeutics (LCTX) over the last 12 years, with Q3 2025 value amounting to -$0.13.
- Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) fell 55000.0% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 14166.67%. This contributed to the annual value of -$0.09 for FY2024, which is 2264.96% up from last year.
- Per Lineage Cell Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.13 for Q3 2025, which was down 55000.0% from -$0.13 recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.02 during Q4 2024, and its lowest value of -$9.12 during Q1 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.04 (2022), whereas its average is -$0.55.
- Over the last 5 years, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) had its largest YoY gain of 9993.01% in 2021, and its largest YoY loss of 1611551.72% in 2021.
- Quarter analysis of 5 years shows Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.05 in 2021, then surged by 35.81% to -$0.03 in 2022, then increased by 8.99% to -$0.03 in 2023, then soared by 40.54% to -$0.02 in 2024, then tumbled by 700.77% to -$0.13 in 2025.
- Its last three reported values are -$0.13 in Q3 2025, -$0.13 for Q2 2025, and -$0.02 during Q1 2025.